News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
698,313 Results
Type
Article (39755)
Company Profile (255)
Press Release (658303)
Multimedia
Podcasts (47)
Webinars (12)
Section
Business (204491)
Career Advice (2036)
Deals (35454)
Drug Delivery (95)
Drug Development (81144)
Employer Resources (172)
FDA (16184)
Job Trends (14873)
News (345667)
Policy (32564)
Tag
2024 BioCapital Digital (7)
2024 BioForest Digital (1)
2024 BioForest Standard (1)
2024 BioMidwest Digital (7)
2024 BioMidwest Standard (1)
2024 Bio NC Digital (4)
2024 Bio NC Standard (1)
2024 Biotech Bay Standard (17)
2024 Biotech Beach Digital (8)
2024 Biotech Beach Standard (5)
2024 Genetown Digital (5)
2024 Genetown Standard (8)
2024 Lone Star Bio Digital (4)
2024 Pharm Country Digital (5)
2024 Pharm Country Standard (4)
2025 BioForest Digital (1)
2025 Lone Star Bio Digital (5)
2026 BioCapital Standard (1)
2026 BioMidwest Elite (1)
2026 Bio NC Standard (1)
2026 Biotech Bay Standard (1)
2026 Biotech Beach Elite (1)
2026 Genetown Elite (2)
2026 Genetown Standard (1)
2026 Pharm Country Standard (2)
Academia (2559)
Accelerated approval (5)
Adcomms (21)
Allergies (82)
Alliances (49495)
ALS (87)
Alzheimer's disease (1371)
Antibody-drug conjugate (ADC) (115)
Approvals (16182)
Artificial intelligence (238)
Autoimmune disease (20)
Automation (15)
Bankruptcy (360)
Best Places to Work (11653)
BIOSECURE Act (18)
Biosimilars (103)
Biotechnology (182)
Bladder cancer (60)
Brain cancer (26)
Breast cancer (261)
Cancer (2081)
Cardiovascular disease (166)
Career advice (1694)
Career pathing (29)
CAR-T (144)
Cell therapy (402)
Cervical cancer (19)
Clinical research (65919)
Collaboration (790)
Compensation (500)
Complete response letters (19)
COVID-19 (2588)
CRISPR (37)
C-suite (222)
Cystic fibrosis (100)
Data (2049)
Decentralized trials (2)
Denatured (17)
Depression (39)
Diabetes (256)
Diagnostics (6358)
Digital health (18)
Diversity (8)
Diversity, equity & inclusion (44)
Drug discovery (117)
Drug pricing (96)
Drug shortages (25)
Duchenne muscular dystrophy (91)
Earnings (86352)
Editorial (33)
Employer branding (21)
Employer resources (146)
Events (112077)
Executive appointments (685)
FDA (17355)
Featured Employer (47)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (7)
Funding (719)
Gene editing (100)
Generative AI (19)
Gene therapy (287)
GLP-1 (697)
Government (4405)
Grass and pollen (4)
Guidances (50)
Healthcare (18849)
Huntington's disease (22)
IgA nephropathy (24)
Immunology and inflammation (108)
Indications (26)
Infectious disease (2726)
Inflammatory bowel disease (134)
Inflation Reduction Act (8)
Influenza (50)
Intellectual property (90)
Interviews (321)
IPO (16514)
IRA (40)
Job creations (3638)
Job search strategy (1438)
Kidney cancer (9)
Labor market (35)
Layoffs (458)
Leadership (16)
Legal (7914)
Liver cancer (72)
Lung cancer (301)
Lymphoma (140)
Machine learning (5)
Management (58)
Manufacturing (277)
MASH (62)
Medical device (13373)
Medtech (13378)
Mergers & acquisitions (19449)
Metabolic disorders (654)
Multiple sclerosis (74)
NASH (16)
Neurodegenerative disease (84)
Neuropsychiatric disorders (24)
Neuroscience (1874)
NextGen: Class of 2025 (6530)
Non-profit (4485)
Northern California (2523)
Now hiring (37)
Obesity (352)
Opinion (203)
Ovarian cancer (74)
Pain (82)
Pancreatic cancer (79)
Parkinson's disease (146)
Partnered (21)
Patents (219)
Patient recruitment (99)
Peanut (46)
People (57384)
Pharmaceutical (63)
Pharmacy benefit managers (18)
Phase I (20544)
Phase II (29028)
Phase III (21625)
Pipeline (1109)
Policy (127)
Postmarket research (2564)
Preclinical (8688)
Press Release (64)
Prostate cancer (98)
Psychedelics (30)
Radiopharmaceuticals (244)
Rare diseases (372)
Real estate (5920)
Recruiting (65)
Regulatory (22235)
Reports (46)
Research institute (2326)
Resumes & cover letters (355)
Rett syndrome (4)
RNA editing (4)
RSV (40)
Schizophrenia (65)
Series A (126)
Series B (81)
Service/supplier (11)
Sickle cell disease (52)
Southern California (2175)
Special edition (14)
Spinal muscular atrophy (147)
Sponsored (28)
Startups (3581)
State (2)
Stomach cancer (13)
Supply chain (65)
Tariffs (22)
The Weekly (28)
United States (21945)
Vaccines (662)
Venture capitalists (37)
Weight loss (229)
Women's health (34)
Worklife (15)
Date
Today (120)
Last 7 days (484)
Last 30 days (2479)
Last 365 days (33079)
2025 (9092)
2024 (35271)
2023 (40138)
2022 (51252)
2021 (55795)
2020 (54159)
2019 (46611)
2018 (35079)
2017 (32161)
2016 (31541)
2015 (37618)
2014 (31379)
2013 (26394)
2012 (28612)
2011 (29307)
2010 (27382)
Location
Africa (719)
Alabama (52)
Alaska (7)
Arizona (229)
Arkansas (13)
Asia (37875)
Australia (6201)
California (5753)
Canada (1934)
China (489)
Colorado (252)
Connecticut (262)
Delaware (134)
Europe (81281)
Florida (855)
Georgia (201)
Idaho (57)
Illinois (509)
India (25)
Indiana (298)
Iowa (9)
Japan (148)
Kansas (103)
Kentucky (23)
Louisiana (9)
Maine (62)
Maryland (858)
Massachusetts (4318)
Michigan (215)
Minnesota (379)
Mississippi (2)
Missouri (78)
Montana (27)
Nebraska (25)
Nevada (59)
New Hampshire (63)
New Jersey (1649)
New Mexico (28)
New York (1642)
North Carolina (938)
North Dakota (7)
Northern California (2523)
Ohio (194)
Oklahoma (14)
Oregon (33)
Pennsylvania (1307)
Puerto Rico (11)
Rhode Island (29)
South America (1101)
South Carolina (19)
South Dakota (1)
Southern California (2175)
Tennessee (99)
Texas (856)
Utah (170)
Virginia (135)
Washington D.C. (60)
Washington State (531)
West Virginia (3)
Wisconsin (51)
698,313 Results for "sab biotherapeutics inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
SAb Biotherapeutics Rebrands as SAB BIO
SAB Biotherapeutics today announced its new name, SAB BIO, and visual identity to more closely align with its mission to treat and prevent immune and autoimmune disorders with the use of its unique immunotherapy platform.
June 20, 2024
·
5 min read
SAB Biotherapeutics Provides SAB-142 Trial Update
SAB Biotherapeutics, Inc. today announced their Chief Medical Officer, Dr. Alexandra Kropotova, MD, MBA disclosed that SAB has completed dosing the third cohort for SAB-142.
April 16, 2024
·
5 min read
SAB Biotherapeutics to Present at INNODIA Annual Meeting
SAB Biotherapeutics, Inc. (Nasdaq: SABS), (“SAB” or the “Company”) today announced their Chief Medical Officer, Dr. Alexandra Kropotova, MD, MBA will share an overview of the SAB-142 clinical development plan and anticipated milestones at the INNODIA Annual Meeting in Leuven, Belgium on April 11, 2024.
April 8, 2024
·
5 min read
Business
SAB Biotherapeutics Announces Q1 2024 Financial Results and Provides Company Updates
SAB Biotherapeutics, Inc. reported financial results for the first quarter ended March 31, 2024, and provided a company update.
May 20, 2024
·
5 min read
SAB Biotherapeutics to Present at the Needham Virtual Healthcare Conference
SAB Biotherapeutics, Inc. (Nasdaq: SABS), (“SAB” or the “Company”) today announced Samuel J. Reich, the company’s Chairman and CEO, will present an overview of the company at the upcoming 23rd Annual Needham Virtual Conference on Thursday, April 11, 2024 at 1:30 p.m. ET.
April 4, 2024
·
3 min read
SAB Biotherapeutics Announces Departure of Chief Financial Officer
SAB Biotherapeutics today announced that effective June 4, its Chief Financial Officer Michael King will be departing the company to accept a role as CEO at a privately-held oncology company.
May 30, 2024
·
4 min read
Policy
FDA Provides Clearance to IND Application for Type 1 Diabetes Therapy SAB-142 by SAB Biotherapeutics
SAB Biotherapeutics, announced that the U.S. Food and Drug Administration has provided clearance for the Company’s investigational new drug application to proceed for its phase 1 clinical trial for type 1 diabetes therapy SAB-142.
May 21, 2024
·
6 min read
SAB Biotherapeutics to Present at the American Diabetes Association 84th Scientific Sessions
SAB Biotherapeutics (Nasdaq: SABS) (the “Company” or “SAB”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform developing a human anti-thymocyte immunoglobulin (hIgG) for delaying the onset or progression of type 1 diabetes (T1D), today announced that it will present a poster at the ADA 84th Scientific Sessions on June 21-24, 2024 in Orlando, Florida.
June 18, 2024
·
5 min read
Business
SAB Biotherapeutics Appoints Jay Skyler, MD, to the Board of Directors
SAB Biotherapeutics announced that Jay Skyler, MD, MACP, FRCP has been appointed to the company’s Board of Directors.
May 6, 2024
·
5 min read
Business
SAB Biotherapeutics Announces Executive Leadership Change
SAB Biotherapeutics, Inc. today announced Samuel J. Reich, currently the Executive Chairman of SAB, will expand his role to include that of Chief Executive Officer of SAB, effective February 2, 2024.
February 2, 2024
·
5 min read
1 of 69,832
Next
